Summary Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to conventional anthracyclines. Confocal microscopy demonstrates predominantly cytoplasmic idarubicin accumulation. This distribution is unaltered by resistance status or the resistance reversing agent verapamil. Our results contrast with studies on conventional anthracycines and suggest that nuclear accumulation may not be a prerequisite for anthracycline cytotoxicity.
Anthracyclines are widely used chemotherapy agents. Thought to act primarily as DNA intercalators (Plosker and Faulds, 1993) they are effective against a wide range of tumours. However, their clinical utility is limited by multidrug resistance (MDR). Cells displaying MDR become resistant both to anthracyclines and to other agents such as the vinca alkaloids, actinomycin D and the epipodophyllotoxins (Plosker and Faulds, 1993; Berman and McBride, 1992) . Typically, MDR cells take up less drug than sensitive equivalents. This phenomenon may result from plasma membrane drug efflux pumps such as P-glycoprotein (P-gp, Moscow et al., 1993) , although the mechanism remains controversial (Roepe, 1992) . Multidrug resistance-associated protein (MRP, Zaman et al., 1994) and lung resistancerelated protein (LRP, Scheffer et al., 1995) have also been recently described as mediating MDR. Because anthracyclines fluoresce, it is possible to visualise their intracellular distribution. Viable sensitive and MDR cells appear to sequester conventional anthracyclines differently (Coley et al., 1993; Gervasoni et al., 1991; Duffy et al., 1996) . Sensitive cells display nuclear drug fluorescence, whereas MDR cells show predominantly cytoplasmic fluorescence. Interestingly, MDR-reversing agents such as verapamil cause the intracellular distribution of these drugs in MDR cells to revert to the sensitive pattern (Coley et al., 1993) .
Idarubicin is a relatively new anthracycline. Of greater lipophilicity than earlier derivatives, it appears more effective than its predecessors, especially in the treatment of tumours resistant to these agents (Berman et al., 1992) . We have studied the distribution of idarubicin fluorescence in sensitive and P-glycoprotein-expressing MDR sublines of the MGHU-1 bladder cancer cell line (Floyd et al., 1990 Confocal microscopy Sensitive and resistant MGH-U1 cells were seeded into 60 mm Petri dishes and reincubated overnight, allowing the cells to adhere. Two hours before microscopy, the medium was changed to HEPES-buffered DMEM with 10 pg ml-' of anthracycline with or without verapamil 25 ,ug ml-'. Cell viability after confocal microscopy was confirmed by trypan blue exclusion (0.02% w/v).
Confocal microscopy was performed using the Leica TCS 4D system, the fibre optic laser emitting at 488 nm. Cells were imaged in the incubation medium using a x 50 water immersion lens. Consistent images were obtained on three separate occasions using identical incubation conditions. Pinhole and electronic variables were kept constant throughout.
MTT cytotoxicity studies Cytotoxicity experiments were performed using the MTT assay (Freshney, 1994 Figure 2b demonstrates idarubicin distribution in MGHU-1-resistant cells. Although this specimen shows reduced idarubicin fluorescence, drug distribution remains similar to the sensitive cells.
Addition of 25 pg ml-' of verapamil to the idarubicin solution increases drug fluorescence in the resistant cells, but appears to make no difference to the distribution of idarubicin fluorescence in either sensitive (Figure 3a) or resistant (Figure 3b ) MGHU-1 cells. MTT cytotoxicity studies confirm the P-gp-expressing subline to 100-fold more resistant to idarubicin (Figure 4) . Addition of 25 pg ml-1 of verapamil reduces this resistance by a factor of ten.
DNA-mediated fluorescence quenching demonstrates that idarubicin fluoresces more strongly in free solution than the related anthracyclines epirubicin and doxorubicin ( Figure 5 ).
Between DNA concentrations of 0.02-0.06 mg ml-', idarubicin demonstrates a greater degree of fluorescence quenching. At greater concentrations, however, the pattern of quenching appears the same.
Discussion
These results contrast with studies performed on conventional anthracyclines by ourselves and others. Using doxodauno-and epirubicin, nuclear drug fluorescence has been associated with sensitivity, and cytoplasmic fluorescence with resistance (Coley et al., 1993; Gervasoni et al., 1991) . Additionally, the morpholinyl-substituted analogue of doxorubicin (MR-DOX) is known to retain activity in MDR cells, and high levels of nuclear MR-DOX fluorescence in MDR cell lines have been demonstrated (Coley et al., 1993) .
Although the precise antineoplastic mechanism of action of anthracyclines is still debated, current evidence suggests that these agents intercalate DNA. They may stabilise the topoisomerase -DNA cleavable complex or inhibit DNA helicase activity, thereby reducing replication and transcrip- tion (Plosker and Faulds, 1993) . As idarubicin is widely regarded as more effective against MDR cells than older anthracyclines (Berman and McBride, 1992) , it is curious that nuclear idarubicin fluorescence should appear diminished in both sensitive and MDR cells. These anomalous findings do not correlate with significantly altered fluorescence quenching. Lankelma et al. (1991) demonstrated 95% fluorescence quenching with daunorubicin and calf thymus DNA. Our own work with doxorubicin, epirubicin and idarubicin shows only minor differences in fluorescence quenching between idarubicin and the two conventional anthracyclines and does not explain the striking differences in nuclear fluorescence observed with the confocal microscope.
These results are also relevant to our understanding of the phenomenon of MDR. Verapamil dramatically increases the nuclear uptake and cytotoxicity of conventional anthracyclines in MDR cells (Coley et al., 1993; Michieli et al., 1994) . (lOpgml-'); (--) , doxorubicin (10 gml-P); ( ), idarubicin (lOpgml-').
Our own MTT cytotoxicity studies confirm that addition of verapamil to idarubicin preparations increases idarubicin cytotoxicity in the MDR MGH-Ul cell line ( Figure 5 ). However, confocal microscopy demonstrates that the addition of verapamil to idarubicin does not restore nuclear drug fluorescence in either the parental or MDR cell line, suggesting that substantial nuclear drug presence may not be a prerequisite for effective anthracycline cytotoxicity in sensitive cells, or for overcoming MDR.
Considerable work remains to be done, both on the putative mechanism of action of anthracyclines, and on the fundamentals of MDR and MDR reversal. We believe that our results are relevant to the continuing study of these mechanisms and that it is premature to assume that nuclear drug fluorescence necessarily correlates with cytotoxicity.
